AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3538802 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy (beta-blockade and calcium antagonists)
Number of subjects: 884
Study 3538802 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited bicycle stress test
Number of subjects: 884
Study 3538802 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables, stress testing, and/or resting radionuclide ventriculography
Number of subjects: 884
Study 3538802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ejection fraction (<40%) and insufficient blood pressure rise (<30 mm Hg) during stress testing
Number of subjects: 884
Study 3538802 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory electrocardiogram
Number of subjects: 884
Study 29520772 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily kiwifruit consumption for 5 months
Number of subjects: 0
Study 29520772 — intervention group
Group type: COMPARATOR
Intervention: Control group (no kiwifruit consumption)
Number of subjects: 0
Study 27804312 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery‐Åsberg Depression Self‐assessment scale (MADRS‐S)
Number of subjects: 9
Study 24150198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed high (FH; 0.067 mg/kg/day)
Number of subjects: 89
Study 24150198 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually adjusted (IA; 0.035 mg/kg/day) after 3 months
Number of subjects: 89
Study 24150198 — intervention group
Group type: COMPARATOR
Intervention: Individually adjusted (IA; 0.035 mg/kg/day) continued low dose
Number of subjects: 89
Study 23869636 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen capture tutorials
Number of subjects: 0
Study 23869636 — intervention group
Group type: COMPARATOR
Intervention: Control variables
Number of subjects: 0
Study 21554564 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 35
Study 21554564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 18794652 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (titrated up to 400 mg/d, then 400-600 mg/d depending on clinical response)
Number of subjects: 40
Study 18794652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16644334 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg twice daily for 3 days then once daily
Number of subjects: 446
Study 16644334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study 12953018 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sodium intake (140 mmol/d)
Number of subjects: 188
Study 12953018 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium sodium intake (104 mmol/d)
Number of subjects: 188
Study 12953018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower sodium intake (62 mmol/d)
Number of subjects: 188
Study 10844829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms kg‐1
Number of subjects: 40
Study 10844829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25-50 micrograms kg‐1
Number of subjects: 40
Study 10844829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 and 150 micrograms kg‐1
Number of subjects: 40
Study 8844441 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 10 mg
Number of subjects: 182
Study 8844441 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 20 mg
Number of subjects: 182
Study 8844441 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 30 mg
Number of subjects: 182
Study 8844441 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release oxycodone 15 mg
Number of subjects: 182
Study 8844441 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release oxycodone 10 mg plus acetaminophen 650 mg (APAP)
Number of subjects: 182
Study 8844441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 1727961 — intervention group
Group type: EXPERIMENTAL
Intervention: Interposed abdominal counterpulsation (IAC) during CPR
Number of subjects: 103
Study 1727961 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 103
Study 6653683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (SRT)
Number of subjects: 19
Study 6653683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30408621 — intervention group
Group type: EXPERIMENTAL
Intervention: SINEMA model (intervention arm)
Number of subjects: 125
Study 30408621 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 125
Study 29248312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses (Group N)
Number of subjects: 544
Study 29248312 — intervention group
Group type: COMPARATOR
Intervention: Physicians (Group P)
Number of subjects: 544
Study 29248312 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 544
Study 29248312 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 544
Study 29248312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 544
Study 29248312 — intervention group
Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 544
Study 29248312 — intervention group
Group type: COMPARATOR
Intervention: Age, job seniority, and type of hospital
Number of subjects: 544
Study 29248312 — intervention group
Group type: EXPERIMENTAL
Intervention: Night shifts and duty overload
Number of subjects: 544
Study 26347514 — intervention group
Group type: EXPERIMENTAL
Intervention: SQT+NAC (N-acetylcysteine 400 mg bid for the first 5 days)
Number of subjects: 99
Study 26347514 — intervention group
Group type: COMPARATOR
Intervention: SQT-only (rabeprazole 20 mg and amoxicillin 1 g for the first 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg for the remaining 5 days)
Number of subjects: 99
Study 26347514 — intervention group
Group type: COMPARATOR
Intervention: SQT-only
Number of subjects: 99
Study 26347514 — intervention group
Group type: EXPERIMENTAL
Intervention: SQT+NAC
Number of subjects: 99
Study 25494054 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g·kg‐1 BICA
Number of subjects: 21
Study 25494054 — intervention group
Group type: COMPARATOR
Intervention: 4 g of sodium chloride (placebo)
Number of subjects: 21
Study 23021296 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received a brief note asking to increase physical activity and sun exposure
Number of subjects: 15
Study 23021296 — intervention group
Group type: COMPARATOR
Intervention: Control group did not receive explicit recommendations
Number of subjects: 15
Study 20068208 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 54
Study 20068208 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 54
Study 20068208 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PRP vs. placebo
Number of subjects: 54
Study 17321097 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet on cigarette additives (n=1074)
Number of subjects: 2152
Study 17321097 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=1078)
Number of subjects: 2152
Study 16267182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate care (IC) service provided by a joint care management team assessing patient need and purchasing support and rehabilitation from sector-based IC teams.
Number of subjects: 1648
Study 16267182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate care (IC) service
Number of subjects: 1648
Study 16267182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IC service)
Number of subjects: 1648
Study 12391531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation (p(et)CO(2)=30 mmHg)
Number of subjects: 120
Study 12391531 — intervention group
Group type: COMPARATOR
Intervention: Normoventilation (p(et)CO(2)=45 mmHg)
Number of subjects: 120
Study 10201671 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg nalmefene
Number of subjects: 120
Study 10201671 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg nalmefene
Number of subjects: 120
Study 10201671 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 8641322 — intervention group
Group type: COMPARATOR
Intervention: SCH 42354 400 mg BID
Number of subjects: 0
Study 8641322 — intervention group
Group type: COMPARATOR
Intervention: SCH 42354 300 mg BID
Number of subjects: 0
Study 8641322 — intervention group
Group type: COMPARATOR
Intervention: SCH 42354 (entire dose range)
Number of subjects: 0
Study 2138704 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ramipril p.o.
Number of subjects: 18
Study 2138704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6158390 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy for 1 week
Number of subjects: 6
Study 6158390 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy for 48 h
Number of subjects: 6
Study 31158253 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological Hall technique (HT)
Number of subjects: 212
Study 31158253 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (CT)
Number of subjects: 212
Study 28726053 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee immobilization brace (KIB)
Number of subjects: 20
Study 28726053 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee immobilizer brace and Foot Lifter Orthosis (FLO)
Number of subjects: 20
Study 28726053 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee immobilization brace (KIB) and rigid taping (RT)
Number of subjects: 20
Study 25981651 — intervention group
Group type: EXPERIMENTAL
Intervention: Hange-shashin-to; administered to 12 patients
Number of subjects: 16
Study 25981651 — intervention group
Group type: COMPARATOR
Intervention: No Hange-shashin-to; 4 patients
Number of subjects: 16
Study 24058300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenofovir and emtricitabine/tenofovir with adherence counseling
Number of subjects: 1147
Study 24058300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1147
Study 21939520 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 μg daily for 3 months)
Number of subjects: 12
Study 21939520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20025153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic catheters
Number of subjects: 56
Study 20025153 — intervention group
Group type: COMPARATOR
Intervention: Standard catheters
Number of subjects: 56
Study 20025153 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reporting of UTI signs and symptoms
Number of subjects: 56
Study 20025153 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs and symptoms of UTI
Number of subjects: 56
Study 18997196 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin, 20 mg daily
Number of subjects: 17802
Study 18997196 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17802
Study 16243115 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (70 microM)
Number of subjects: 38
Study 16243115 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (20 microM)
Number of subjects: 38
Study 16243115 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol combined with l-NOARG (10(‐4) M)
Number of subjects: 38
Study 16243115 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (10(‐5) M)
Number of subjects: 38
Study 11876271 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 masticatory cycles
Number of subjects: 12
Study 11876271 — intervention group
Group type: COMPARATOR
Intervention: 25 masticatory cycles (swallowing ham cubes whole)
Number of subjects: 12
Study 10202985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine-induced inflammation markers (IL-1ra, ESR, CRP, PMNL count)
Number of subjects: 41
Study 7595908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose verapamil
Number of subjects: 0
Study 7595908 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and nifedipine
Number of subjects: 0
Study 7595908 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 0
Study 2205287 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft vacuum extractor cups (Silc or Silastic)
Number of subjects: 0
Study 2205287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid vacuum extractor cups (New Bird or O'Neil)
Number of subjects: 0
Study 69938 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical thrombin applied locally to the wound
Number of subjects: 45
Study 69938 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thrombin applied)
Number of subjects: 45
Study 31010412 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention program
Number of subjects: 22
Study 28803124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum with moderate neuromuscular blockade (1-3 TOF)
Number of subjects: 90
Study 28803124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum with deep neuromuscular blockade (1-5 PTC)
Number of subjects: 90
Study 28803124 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12mmHg)
Number of subjects: 90
Study 25811395 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet‐mediated, pedometer‐based exercise intervention
Number of subjects: 239
Study 25811395 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (pedometer)
Number of subjects: 239
Study 23437966 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (6 weeks)
Number of subjects: 30
Study 23437966 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (after 6 weeks of paroxetine)
Number of subjects: 30
Study 23437966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (after long-term paroxetine treatment)
Number of subjects: 30
Study 23437966 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (long-term treatment, 18.7 weeks on average)
Number of subjects: 30
Study 21752726 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (identically-looking placebo drug)
Number of subjects: 45
Study 21752726 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (homeopathic remedy)
Number of subjects: 45
Study 21752726 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 45
Study 18515447 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 8 mg
Number of subjects: 12
Study 17070276 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 204
Study 17070276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 12798881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.625 mg of esterified estrogens and 1.25 mg of methyltestosterone
Number of subjects: 218
Study 12798881 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg of esterified estrogens
Number of subjects: 218
Study 10951298 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild vascular dilation and tortuosity insufficient for plus disease
Number of subjects: 32
Study 10951298 — intervention group
Group type: COMPARATOR
Intervention: Normal posterior poles
Number of subjects: 32
Study 8979385 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority group relevant to self-definition
Number of subjects: 0
Study 8979385 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority group negatively self-relevant
Number of subjects: 0
Study 1475511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK)
Number of subjects: 510
Study 1475511 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with fibrinolytic agents)
Number of subjects: 510
Study 6383615 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 25 mg + Hydrochlorothiazide (HCT) 25 mg BID
Number of subjects: 20
Study 6383615 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol (OXP) 80 mg + Chlorthalidone (CHLT) 10 mg BID
Number of subjects: 20
Study 30836169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad training (50 min with instructional videos and hands-on exercises)
Number of subjects: 330
Study 30836169 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led training (2 hours in groups of six)
Number of subjects: 330
Study 30836169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad training
Number of subjects: 330
Study 30836169 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 330
Study 29906455 — intervention group
Group type: EXPERIMENTAL
Intervention: FITOPROT A - mucoadhesive formulation containing 10 mg/mL of curcuminoids extract plus 20% v/v of Bidens pilosa L. extract
Number of subjects: 20
Study 29906455 — intervention group
Group type: EXPERIMENTAL
Intervention: FITOPROT B - mucoadhesive formulation containing 20 mg/mL of curcuminoids extract plus 40% v/v of Bidens pilosa L. extract
Number of subjects: 20
Study 27491226 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine Capsule (BC) 300 mg, thrice per day for 3 months
Number of subjects: 102
Study 27491226 — intervention group
Group type: COMPARATOR
Intervention: Placebo 300 mg, thrice per day for 3 months
Number of subjects: 102
Study 25208824 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (Deep brain stimulation of the basolateral amygdala)
Number of subjects: 6
Study 25208824 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control group)
Number of subjects: 6
Study 25208824 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label stimulation (after initial phase)
Number of subjects: 6
Study 22333403 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus introduction with calcineurin inhibitor (CNI) reduction
Number of subjects: 282
Study 22333403 — intervention group
Group type: COMPARATOR
Intervention: Standard CNI therapy
Number of subjects: 282
Study 20150170 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention (Check Your Drinking - CYD)
Number of subjects: 185
Study 20150170 — intervention group
Group type: COMPARATOR
Intervention: Control condition (written description of CYD components)
Number of subjects: 185
Study 18574391 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (75 mg/day with a 300 mg loading dose for 14 days)
Number of subjects: 42
Study 18574391 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 42
Study 16042934 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064 nm Nd:YAG laser
Number of subjects: 12
Study 16042934 — intervention group
Group type: COMPARATOR
Intervention: 1,320 nm Nd:YAG laser
Number of subjects: 12
Study 12358325 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV + LTOT
Number of subjects: 122
Study 12358325 — intervention group
Group type: COMPARATOR
Intervention: LTOT alone
Number of subjects: 122
Study 10513855 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 29
Study 7498103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with a physiological dose of water‐soluble vitamins (fortified fruit juice containing 50 g carbohydrate and 50% of the daily dietary recommendations of water‐soluble vitamins)
Number of subjects: 42
Study 7498103 — intervention group
Group type: COMPARATOR
Intervention: Regular fruit juice (placebo)
Number of subjects: 42
Study 1780420 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 62
Study 1780420 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 62
Study 1780420 — intervention group
Group type: COMPARATOR
Intervention: 0 mg nicotine gum
Number of subjects: 62
Study 1780420 — intervention group
Group type: COMPARATOR
Intervention: Cigarette withdrawal
Number of subjects: 62
Study 7048948 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 25 mg/kg body weight
Number of subjects: 62
Study 7048948 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 35 mg/kg body weight
Number of subjects: 62
Study 31779856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low contrast delivery technique (ULCD)
Number of subjects: 204
Study 31779856 — intervention group
Group type: COMPARATOR
Intervention: Standard automated contrast injector system (ACIS)
Number of subjects: 204
Study 31779856 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (ULCD)
Number of subjects: 204
Study 31779856 — intervention group
Group type: COMPARATOR
Intervention: Overall (ACIS)
Number of subjects: 204
Study 29425836 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based daily feedback and communication platform
Number of subjects: 120
Study 29425836 — intervention group
Group type: COMPARATOR
Intervention: Routine biweekly prenatal clinic care (control group)
Number of subjects: 120
Study 27168899 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated discussion group intervention (18 sessions)
Number of subjects: 51
Study 27168899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study 24763866 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Significant Medication Errors (CSME)
Number of subjects: 200
Study 24763866 — intervention group
Group type: EXPERIMENTAL
Intervention: CSME
Number of subjects: 200
Study 23036274 — intervention group
Group type: EXPERIMENTAL
Intervention: Real words (DARK/PARK)
Number of subjects: 0
Study 23036274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronounceable pseudowords (DARL/PARL)
Number of subjects: 0
Study 23036274 — intervention group
Group type: EXPERIMENTAL
Intervention: 11‐year‐olds ERP response
Number of subjects: 0
Study 23036274 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐year‐olds ERP response
Number of subjects: 0
Study 20453626 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 71
Study 20453626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 20453626 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 18540858 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16114160 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to molds extracts
Number of subjects: 85
Study 16114160 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to grass pollen extracts
Number of subjects: 85